Global Systemic Lupus Erythematosus Treatment Market Overview 2033 : Forecasted Market Size And Growth Rate | GlaxoSmithKline plc, Aurinia Pharmaceuticals Inc., Pfizer Inc., Merck & Co Inc

"The new report published by The Business Research Company, titled ""Systemic Lupus Erythematosus Treatment Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033"", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the systemic lupus erythematosus treatment market size has grown rapidly in recent years. It will grow from $2.76 billion in 2023 to $3.06 billion in 2024 at a compound annual growth rate (CAGR) of 10.7%. The systemic lupus erythematosus treatment market size is expected to see rapid growth in the next few years. It will grow to $4.66 billion in 2028 at a compound annual growth rate (CAGR) of 11.1%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=9163&type=smp

Rising Incidence Of Autoimmune Disorders Fuels Growth In The Systemic Lupus Erythematosus Treatment Market
The rising number of autoimmune disorders is expected to propel the growth of the systemic lupus erythematosus treatment market going forward. An autoimmune disease refers to a condition in which a patient's immune system attacks his or her body. An autoimmune disease occurs when the immune system mistakes parts of the body as foreign. The body releases proteins called autoantibodies that attack healthy cells. Systemic lupus erythematosus refers to an autoimmune disease that causes the immune system to attack its tissues, causing widespread inflammation and tissue damage in the affected organs. It affects the joints, skin, brain, lungs, kidneys, and blood vessels. For instance, in May 2023, according to the University of Oxford, a UK-based research university, autoimmune disorders affect 10% of the world's population, with 13% of women and 7% of males affected. Furthermore, in October 2021, according to an article shared by the City, University of London, a UK-based public research university, 4 million people in the UK, or 7% of the population, are estimated to have at least one autoimmune disease. Over 80 autoimmune disorders have been found, and their prevalence is increasing annually by 3-9%. Thus, the rising number of autoimmune disorders is driving the growth of the systemic lupus erythematosus treatment market.

Increasing Focus On Product Approvals To Provide Reliable Services To Their Customers
Major companies operating in the systemic lupus erythematosus treatment market are focusing on product approvals such as saphnelo to drive revenues in their market. Saphnelo (anifrolumab-fnia) is a prescription medicine used to treat adults with systemic lupus erythematosus (SLE) ranging from moderate to severe who are also taking other lupus medications. For instance, in August 2021, AstraZeneca PLC, a Sweden-based pharmaceutical company received FDA approval for anifrolumab-fnia (Saphnelo) which is used for the treatment of moderate to severe systemic lupus erythematosus (SLE) in adults. This is the first time a type I interferon (type I IFN) receptor antagonist has been approved. The pathophysiology of lupus is largely dependent on type I interferon (IFN), and higher levels of type I IFN signaling are linked to more active and severe disease.

The systemic lupus erythematosus treatment market covered in this report is segmented -

1) By Drug: Antimalarial Drugs, Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Corticosteroids, Immunosuppressive Drugs
2) By Route Of Administration: Sub-Cutaneous, Oral, Intravenous
3) By Application: Hospital Pharmacies, Retail Pharmacies, Online Sales

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=9163&type=discount

Major companies operating in the systemic lupus erythematosus treatment market report are GlaxoSmithKline plc, Aurinia Pharmaceuticals Inc., Pfizer Inc., Merck & Co Inc., Anthera Pharmaceuticals Inc., AstraZeneca plc, Bristol-Myers Squibb Company Inc., F. Hoffmann-La Roche Ltd., ImmuPharma plc, Sanofi SA, Eli Lilly and Company, Amgen Inc., Johnson & Johnson Services Inc., Lycera Corporation, Roche Holding AG, Bayer AG, Novartis International AG, Viatris Inc., Swedish Orphan Biovitrum AB, Union Chimique Belge SA, Biogen Inc., Horizon Therapeutics plc, Gilead Sciences Inc., Daiichi Sankyo Company Limited, EMD Serono Inc., Hoth Therapeutics Inc., Zylo Therapeutics Inc., Kyowa Kirin Co. Ltd., Priothera Ltd., Centessa Pharmaceuticals plc, AbbVie Inc., Astellas Pharma Inc., Boehringer Ingelheim International GmbH, Celgene Corporation, Eisai Co. Ltd., Mallinckrodt Pharmaceuticals, Regeneron Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited .

Contents of the report:
1. Executive Summary
2. Systemic Lupus Erythematosus Treatment Market Report Structure
3. Systemic Lupus Erythematosus Treatment Market Trends And Strategies
4. Systemic Lupus Erythematosus Treatment Market - Macro Economic Scenario
5. Systemic Lupus Erythematosus Treatment Market Size And Growth
…..
27. Systemic Lupus Erythematosus Treatment Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/systemic-lupus-erythematosus-treatment-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ "

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.